Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim International GmbH

www.boehringer-ingelheim.com

Latest From Boehringer Ingelheim International GmbH

Newbie Remogliflozin Gives Competition A Run For Their Money

Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.

Commercial Strategy

Who's In And Who's Out In China's Largest Reimbursed Drug List Revamp?

Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.

China Reimbursement

FDA Publishes Immunogenicity Guidelines For Biosimilar Insulins

In a move that will likely be welcomed by industry, the US FDA has issued draft guidance stating that sponsors will generally not need to conduct comparative clinical immunogenicity studies in developing biosimilar/interchangeable products.

Biosimilars Regulation

Biosimilar Insulins (Generally) Won't Need Comparative Clinical Immunogenicity Data, US FDA Says

In a move that will likely be welcomed by industry, the US FDA issued draft guidance stating that sponsors will generally not need to conduct comparative clinical immunogenicity studies in developing biosimilar/interchangeable products.

Biosimilars Metabolic Disorders
See All

Company Information

UsernamePublicRestriction

Register